Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma

Systematic review

Authors

  • Babette J.A. Verkouteren Department of Dermatology, Maastricht University Medical Center+, P. Debyelaan 25, NL-6229 HX Maastricht, The Netherlands
  • Kelly A.E. Sinx
  • Marie G.H.C. Reinders
  • Maureen J.B. Aarts
  • Klara Mosterd

DOI:

https://doi.org/10.2340/actadv.v102.980

Keywords:

basal cell nevus syndrome, high-frequency, hedgehog pathway inhibitor, basal cell carcinoma, oral, topical

Abstract

Some patients with basal cell carcinoma develop a large number of basal cell carcinomas during their lives. The most common underlying genetic disease that causes multiple basal cell carcinomas is basal cell naevus syndrome. Basal cell naevus syndrome is caused by a germline mutation in patched-1 (PTCH1), a tumour suppressor gene of the hedgehog signalling pathway. However, in a significant portion of patients with multiple basal cell carcinomas, no underlying genetic cause is found. Nevertheless, these patients can experience a treatment burden comparable to that of patients with basal cell naevus syndrome. They are referred to as high-frequency basal cell carcinoma patients. Hedgehog pathway inhibitors were the first group of targeted therapy for basal cell carcinomas. This study reviews the literature on hedgehog pathway inhibitor therapy for patients with basal cell naevus syndrome or high-frequency basal cell carcinoma, to provide an overview on efficacy, safety, dosing regimens, tumour resistance and reoccurrence, and health-related quality of life.

Downloads

Download data is not yet available.

References

Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010; 152A: 327-332.

https://doi.org/10.1002/ajmg.a.33139

Lo Muzio L, Nocini PF, Savoia A, Consolo U, Procaccini M, Zelante L, et al. Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals. Clin Genet 1999; 55: 34-40.

https://doi.org/10.1034/j.1399-0004.1999.550106.x

Verkouteren BJA, Cosgun B, Reinders M, Kessler P, Vermeulen RJ, Klaassens M, et al. A guideline for the clinical management of basal cell nevus syndrome (Gorlin-Goltz syndrome). Br J Dermatol 2022; 186: 215-226.

https://doi.org/10.1111/bjd.20700

Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer 2019; 118: 10-34.

https://doi.org/10.1016/j.ejca.2019.06.003

Work G, Invited R, Kim JYS, Kozlow JH, Mittal B, Moyer J, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol 2018; 78: 540-559.

https://doi.org/10.1016/j.jaad.2017.10.006

Huq AJ, Bogwitz M, Gorelik A, Winship IM, White SM, Trainer AH. Cohort study of Gorlin syndrome with emphasis on standardised phenotyping and quality of life assessment. Intern Med J 2017; 47: 664-673.

https://doi.org/10.1111/imj.13429

Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res 2013; 19: 2289-2293.

https://doi.org/10.1158/1078-0432.CCR-12-1956

Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell 2015; 27: 342-353.

https://doi.org/10.1016/j.ccell.2015.02.002

Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 2015; 27: 327-341.

https://doi.org/10.1016/j.ccell.2015.02.001

Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 2015; 16: 729-736.

https://doi.org/10.1016/S1470-2045(15)70198-1

Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366: 2180-2188.

https://doi.org/10.1056/NEJMoa1113538

Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016; 17: 1720-1731.

https://doi.org/10.1016/S1470-2045(16)30566-6

Verkouteren BJA, Wakkee M, Reyners AKL, Nelemans P, Aarts MJB, Racz E, et al. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study. Br J Cancer 2021; 124: 1199-1206.

https://doi.org/10.1038/s41416-020-01220-w

Lear JT, Hauschild A, Stockfleth E, Squittieri N, Basset-Seguin N, Dummer R. Efficacy and safety of sonidegib in adult patients with nevoid basal cell carcinoma syndrome (Gorlin Syndrome): results from a Phase 2, double-blind, randomized trial. Clin Cosmet Investig Dermatol 2020; 13: 117-121.

https://doi.org/10.2147/CCID.S233097

Dreno B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol 2017; 18: 404-412.

https://doi.org/10.1016/S1470-2045(17)30072-4

Yang X, Dinehart SM. Intermittent vismodegib therapy in basal cell nevus syndrome. JAMA Dermatol 2016; 152: 223-224.

https://doi.org/10.1001/jamadermatol.2015.3210

Valenzuela-Onate CA, Magdaleno-Tapial J, Garcia-Legaz Martinez M, Perez-Pastor G, Sanchez Carazo JL. Drug holiday approach for Vismodegib treatment in patients with nevoid basal cell carcinoma syndrome: three cases from real clinical practice. Dermatol Ther 2020: 33: e13540.

https://doi.org/10.1111/dth.13540

Mendes SR, Brinca A, Vieira R. Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas in gorlin-goltz syndrome. Available from https://www.wcd2019milan-dl.org/abstract-book/documents/abstracts/39-skin-cancer/vismodegib-hedgehog-signaling-inhibition-and-5398.pdf.

Hoffmann V, Husak R, Maiwirth F, Sasama B, Zahn A, Guski S, et al. Sonidegib in a patient with multiple basal cell carcinomas and HIV infection. J Dtsch Dermatol Ges 2021; 19: 592-594.

https://doi.org/10.1111/ddg.14355

Tronconi MC, Solferino A, Giordano L, Borroni R, Mancini L, Santoro A. Tailored toxicity-driven administration of vismodegib in patients with multiple or locally advanced basal cell carcinoma: a pilot analysis. Front Oncol 2020; 10: 563404.

https://doi.org/10.3389/fonc.2020.563404

Villani A, Costa C, Fabbrocini G, Scalvenzi M. Drug holiday regimen for vismodegib treatment in patients with multiple primary basal cell carcinomas. Dermatol Ther 2020; 33: e13707.

https://doi.org/10.1111/dth.13707

Sohn GK, Kwon GP, Bailey-Healy I, Mirza A, Sarin K, Oro A, et al. Topical itraconazole for the treatment of basal cell carcinoma in patients with basal cell nevus syndrome or high-frequency basal cell carcinomas: a Phase 2, open-label, placebo-controlled trial. JAMA Dermatol 2019; 155: 1078-1080.

https://doi.org/10.1001/jamadermatol.2019.1541

Epstein EH, Lear JT, Saldanha G, Tang JY, Harwoord C. Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome. J Clin Oncol 2018; 36: 15_suppl.

https://doi.org/10.1200/JCO.2018.36.15_suppl.e21626

Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011; 131: 1735-1744.

https://doi.org/10.1038/jid.2011.48

Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol 2012; 148: 1324-1325.

https://doi.org/10.1001/archdermatol.2012.2354

Sinx KAE, Roemen G, van Zutven V, Janssen R, Speel EM, Steijlen PM, et al. Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: clinical approach and genetic analysis. JAAD Case Rep 2018; 4: 408-411.

https://doi.org/10.1016/j.jdcr.2017.11.011

Banvolgyi A, Anker P, Lorincz K, Kiss N, Marton D, Fesus L, et al. Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects. J Dermatolog Treat 2020; 31: 387-398.

https://doi.org/10.1080/09546634.2019.1601155

Wolfe CM, Green WH, Cognetta AB, Jr., Hatfield HK. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg 2012; 38: 1863-1866.

https://doi.org/10.1111/j.1524-4725.2012.02513.x

Tauber G, Pavlovsky L, Fenig E, Hodak E. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp. J Am Acad Dermatol 2015; 73: 799-801.

https://doi.org/10.1016/j.jaad.2015.07.016

Kirkpatrick E, Dobriansky D, Scurry J. Gorlin syndrome, vulvar basal cell carcinomas, vismodegib, and lichen sclerosus: from the ISSVD Case Consultation Committee. J Low Genit Tract Dis 2016; 20: e40-e41.

https://doi.org/10.1097/LGT.0000000000000209

Soura E, Plaka M, Dessinioti C, Syrigos K, Stratigos AJ. Can hair re-growth be considered an early clinical marker of treatment resistance to Hedgehog inhibitors in patients with advanced basal cell carcinoma? A report of two cases. J Eur Acad Dermatol Venereol 2016; 30: 1726-1729.

https://doi.org/10.1111/jdv.13754

Piccerillo A, Di Stefani A, Costantini A, Peris K. Sonidegib after vismodegib discontinuation in a patient with Gorlin-Goltz syndrome and multiple basal cell carcinomas. Dermatol Ther 2021; 34: e15095.

https://doi.org/10.1111/dth.15095

Van Eecke L, Wolter P, Bechter O, Rogiers A, De Smedt J, Garmyn M. P129: Long-term follow-up of two patients with nevoid basal cell carcinoma syndrome (NBCCS) treated with vismodegib. Melanoma Res 2016; 26: e75-e76.

Kesireddy M, Mendiola VL, Jana B, Patel S. Long-term response to vismodegib in a patient with Gorlin-Goltz syndrome: a case report and review of pathological mechanisms involved. Cureus 2019; 11: e5383.

https://doi.org/10.7759/cureus.5383

Schadendorf D, Hauschild A, Fosko S, Zloty D, Labeille B, Grob JJ, et al. Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study. J Eur Acad Dermatol Venereol 2020; 34: e526-e529.

https://doi.org/10.1111/jdv.16446

Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2007; 127: 1351-1357.

https://doi.org/10.1038/sj.jid.5700740

Sohn GK, Kwon GP, Bailey-Healy I, Mirza A, Sarin K, Oro A, et al. Topical itraconazole for the treatment of basal cell carcinoma in patients with basal cell nevus syndrome or high-frequency basal cell carcinomas: a Phase 2, open-label, placebo-controlled trial. JAMA Dermatol 2019; 155: 1078-1080.

https://doi.org/10.1001/jamadermatol.2019.1541

Downloads

Additional Files

Published

2022-06-21

How to Cite

Verkouteren, B. J., Sinx, K. A., Reinders, M. G., Aarts, M. J., & Mosterd, K. (2022). Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma: Systematic review. Acta Dermato-Venereologica, 102, adv00741. https://doi.org/10.2340/actadv.v102.980

Issue

Section

Review

Categories